Skip to main content
  1. Right Decisions
  2. Scottish Palliative Care Guidelines
  3. Medicines information
  4. Back
  5. Pain medicines / analgesics
  6. Methadone
Announcements and latest updates

Right Decision Service newsletter: October 2024

Welcome to the Right Decision Service (RDS) newsletter for October 2024.

1.Contingency arrangements for RDS outages

Development of the contingency solutions to maximise RDS resilience and minimise risk of future outages is in progress, aiming for completion by Christmas. As a reminder, these contingency arrangements  are:

  • Optimising mobile app build process
  • Mobile app always to be downloadable.
  • Serialising builds to mobile app; separate mobile app build from other editorial and end-user processes
  • Load balancing – provides failover (also enables separation of editorial processes from other processes to improve performance.)

 

In the meantime, a gentle reminder to encourage users to download essential clinical toolkits to their mobile devices so that there is an offline version always available.

 

2. New deployment with improvements.

A new scheduled deployment with minor improvements drawn from support tickets, externally funded projects, information related to outages, and feature requests will take place in early December. Key improvements planned are:

  • Deep-linking to individual toolkits within the RDS mobile app. Each toolkit will now have its own direct URL and QR code, both accessible from the app. These can be used to download the toolkit directly where users already have the RDS app installed. If the user does not yet have the RDS app installed, they will be taken to the app store to install the app and immediately afterwards the toolkit will automatically open and download. Note that this will go live a few days later than the improvements below due to the need to link up the mobile front end to the changes in the content management system.
  • Introducing an Announcement Header field to replace the hardcoded "Announcements and latest updates" text. This will enable users to see at a glance the focus of new announcements.
  • Automated daily emptying of the recycling bin (with a 30 day rolling grace period)  in the content management system. A bug preventing complete emptying of the recycling bin contributed to one of the outages earlier this year.
  • Supporting multiple passcodes (ticket 6079)
  • Expanding accordion section to show location of a search result rather than requiring user coming from a search result to manually open all sections and search again for the term.
  • Displaying first accordion section Content text as a snippet on the search results page as a fallback if default/main content is not provided
  • Displaying the context of each search result in the form of a link to the relevant parent tool/section. This will help users to choose which search result is most likely to be appropriate for their needs.
  • As part of release of the new national benzodiazepine quality prescribing guidance toolkit sponsored by Scottish Government Effective Prescribing and Therapeutics, a digital tool to support creation of benzodiazepine tapering/withdrawal schedules.

We are also seeking approval to use the NHS Scotland logo and title for the RDS app on the app stores to help with audience engagement and clarity around the provenance of RDS.

3. RDS Search, Browse and Archive/Version control enhancements

We are still hopeful that user acceptance testing for at least the Search and browse enhancements can take place before Christmas. Thank you for your patience and understanding in waiting for these improvements. Timescales have been pushed back by old app migration challenges, work to address outages, and most recently implementing the contingency arrangements.

4. Support tickets

We are aware that there continue to be some issues around a number of RDS support tickets, in part due to constraints around visibility for the RDS team of the tickets in the existing  support portal. We are investigating the potential to move to a new support ticket requesting system from early in the new year. We will organise the proposed webinar around support ticket processes once we have confirmed the way forward with the system.

Table formatting

There is a known issue with alterations in formatting of some RDS tables which seems to have arisen as a result of the 17 October deployment. Tactuum is working on a fix and on implementing additional regression testing to prevent this issue recurring.

5. New RDS toolkits

Recently launched toolkits include:

NHS Lothian Infectious Diseases

Scottish Health Technologies Group – Technology Assessment recommendations

NHS Tayside Anaesthetics and Critical Care projects – an innovative toolkit which uses PowerAutomate to manage review and response to proposals for improvement projects.

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

A number of toolkits are expected to go live before Christmas, including:

  • Focus on dementia
  • Highland Council Getting it Right for Every Child
  • Dumfries and Galloway Adult Support and Protection procedures
  • National Waiting Well toolkit
  • Fertility Scotland National Network
  • NHS Lothian postural care for care homes

6.Sign up to RDS Editors Teams channel

We have had a good response to the recent invitation to sign up to the new Teams channel for RDS editors. This provides a forum for editors to share learning, ideas and questions and we hope to hold regular webinars on topics of interest.  The RDS team is in the process of joining participants to the channel and we’d encourage all editors to take part, using the registration form – available in Providers section of the RDS Learning and Support area.

 

7. Evaluation projects

The RDS team has worked with colleagues in NHS Grampian and the Digital Health & Care Innovation Centre to evaluate the impact of the Prevent the progress of diabetes web and mobile app in a small-scale pilot project. This app provides access to local and national resources and services targeted at people with prediabetes, a history of gestational diabetes, or candidates for remission. After just 8 weeks of using the app, 94% of patients reported increased their knowledge and understanding of diabetes, and 88% said it had increased their confidence and motivation to make lifestyle changes, highlighting specific behaviour changes. The learning from this project is informing development of a service model based on tailored support for patient groups with, high, medium and low digital self-efficacy.

Please contact ann.wales3@nhs.scot if you would like to know more about this project.

  1. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 29th November 3-4 pm
  • Thursday 5 December 3.30 -4.30 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

The Right Decision Service:  the national decision support platform for Scotland’s health and care

Website: https://rightdecisions.scot.nhs.uk    Mobile app download:  Apple  Android

 

 

Methadone

Red – For medicines normally initiated and used under specialist guidance

Introduction

The information below is intended as a guide for use in primary and secondary care to support the management of patients receiving methadone as a third-line analgesic for complex pain. 

Methadone should only be started by a consultant in palliative medicine and patients require ongoing specialist supervision.  

 

Description

Methadone is a potent, synthetic opioid. Methadone has complex pharmacokinetics and a long half-life. There is a risk of accumulation, especially in elderly patients.

Preparations

Tables are best viewed in landscape mode on mobile devices

Oral Methadone tablets

Methadone liquid
5mg (preferred form)

1mg/ml (green)

10mg/ml (blue)
Injection Methadone injection 10mg/ml (1ml, 2ml, 3.5ml, 5ml ampoules)

 

Indications

Methadone is only used as a third-line opioid for patients with complex pain that is poorly responsive to other opioids, or where these opioids have resulted in intolerable side effects.

  • Patient has responded poorly or had intolerable side effects from first and second-line opioids (for example morphine, diamorphine, oxycodone, fentanyl).
  • In complex neuropathic pain: if the patient has not responded to first and second-line opioid and adjuvant analgesic combinations.
  • In end-stage chronic kidney disease (eGFR less than 30ml/min).

Adjuvant methadone may also be used for the above indications under specialist supervision.

 

Cautions

Methadone should always be used with caution but particularly in the following situations.

  • Methadone has a long and unpredictable half-life which can lead to side effects/severe opioid toxicity without a change in the regular dose, particularly when methadone is started for the first time – careful monitoring is needed.
  • Patients with incident pain or unstable pain where repeated doses of methadone may accumulate and cause opioid toxicity.
  • Pain suspected to have a strong psychological component as repeated demands for as needed doses of methadone may lead to opioid toxicity.

 

Drug interactions:

  • Hepatic methadone metabolism varies considerably between individuals and this variability is responsible for the large differences in methadone clearance and the doses needed to manage pain. 
  • QTMethadone levels may increase if given with fluoxetine, sertraline, clarithromycin, ciprofloxacin, fluconazole. Methadone should not be given with monoamine oxidase inhibitors (for example phenelzine and linezolid) or within 2 weeks of stopping them.
  • Methadone levels may decrease if given with phenytoin, phenobarbital, carbamazepine, St John’s Wort.
  • Concurrent administration with medications that affect methadone metabolism via the hepatic cytochrome P450 system (CYP3A4) – refer to British National Formulary (BNF). Methadone can cause QT prolongation – caution with other drugs that may have this effect, for example QTclarithromycin, amitriptyline, QTcitalopram, QTdomperidone, prochlorperazine, QThaloperidol, QTamiodarone. Refer to BNF.

 

Liver impairment: Reduced clearance. Dose reduction may be necessary.

Renal impairment: No dose reduction necessary. Not significantly removed by dialysis.

 

Side effects

  • Patient may become unexpectedly drowsy or develop respiratory depression particularly when first starting methadone – refer to cautions above.
  • Side effects that are common to all opioids, including dry mouth, constipation may be less common.

 

Dose and administration

  • Patients starting methadone will usually require inpatient admission for 5 to 7 days. A stable methadone dose for 48 to 72 hours before discharge is needed.  
  • Methadone may occasionally be started safely as an adjuvant analgesic for selected patients in the community. The palliative care specialist will recommend an individual dosing regimen and discuss and review the management plan with the patient’s GP.
  • Methadone is usually given twice daily (occasionally three times daily). 
  • A shorter acting opioid than methadone is often used for breakthrough pain in patients on a stable methadone dose. 
  • The methadone dose and the timing of doses should not be changed without instructions from a palliative medicine specialist.

 

Discontinuing methadone: Seek specialist advice.

This may be needed if treatment is ineffective, the patient is experiencing side effects, is unable to take oral medication or is in the last days of life.

 

Practice points

  • Undertake an individual risk assessment prior to initiating methadone. Consider if drug diversion/misuse is likely and if weekly/twice weekly dispensing from a community pharmacy is required.
  • Discuss the methadone prescription with the GP and provide written information.
  • Ensure the GP is aware which methadone preparation should be prescribed if the patient is receiving methadone liquid.
  • Ensure the patient is reviewed by a member of the specialist palliative care team as soon as possible after discharge (within 2 to 3 days).
  • Discuss the prescription with community pharmacy and explain methadone has been prescribed for pain management not drug dependency.

 

References

Blackburn D. Methadone: the analgesic. European Journal of Palliative Care 2005;12:188-191.

Nicholson AB. Methadone for cancer pain. Cochrane database of systematic reviews 2008;(4). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003971.pub3/pdf/standard

Prommer EE. Methadone for cancer pain. Palliative Care: Research & treatment 2010; 4(1-10).

Twycross R et al. Palliative Care Formulary (4th Ed). Palliativedrugs.com Ltd, Nottingham, 2011.

Acknowledgement: Brown DJF. Methadone for cancer pain: A reference for specialists. St Columba’s Hospice, Edinburgh, 2007.